Procept BioRobotics Raises $118 Million

Palo Alto – March 19, 2018 – Cooley advised Procept BioRobotics on its $118 million equity financing round led by Viking Global Investors. Partner Mark Weeks led the Cooley team advising Procept.

In addition to Viking Global, the round included participation from new investor Perceptive Advisors and existing investor CPMG. The new funds will support the worldwide commercialization of Procept’s Aquablation therapy for the minimally invasive treatment of benign prostatic hyperplasia (BPH).

“Our investors share our vision to make Aquablation therapy the new standard of care and treatment of choice for BPH,” said Nikolai Aljuri, Procept’s CEO, in a news release. 
Procept’s Aquabeam System is the first FDA-granted surgical robot providing autonomous tissue removal for the treatment of BPH. It is commercially available in the US, Canada, Australia, New Zealand and select European markets.

Based in Silicon Valley, Procept is a privately held surgical robotics company enabling better patient care by developing transformative solutions in urology.

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.